ERAS-0015
Small Molecule Target: RAS, Cyclophilin A
Erasca
Most recent annual filing: 2026-03-15
- ERAS-4001 Ph1 interim2H 2026ERAS-4001 Ph1 interim, 2H 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Discontinued (4)
- naporafenib — undisclosed · strategic decision to stop development; license termination notice sent to Novartis in March 2026
- ERAS-007 — undisclosed · deprioritized; Asana License Agreement terminated effective November 8, 2025
- ERAS-601 — undisclosed · deprioritized; NiKang License Agreement terminated effective October 9, 2025
- ERAS-801 — Glioblastoma · deprioritized; Katmai License Agreement terminated as of April 1, 2025; rights assigned back to Katmai
Biotech Distilled coverage (10)
- 2026-08-24 UPDATE: Erasca (ERAS) - The FDA Just Answered a Question I Had Been Asking Since April 🔒 Paid
- 2026-08-11 UPDATE: Erasca (ERAS) - They Just Hired the Pancreatic Cancer Guy 🔒 Paid
- 2026-07-13 UPDATE: Erasca (ERAS) - The Data Rehabilitates, and Management Raises $500M Anyway 🔒 Paid
- 2026-05-12 UPDATE: Erasca (ERAS) - A $150M Mea Culpa and a Merck Wrinkle 🔒 Paid
- 2026-04-29 UPDATE: Erasca (ERAS) - A Buried Phase 1 Fatality and the Rapid Collapse of ERAS-0015 🔒 Paid
- 2026-04-28 UPDATE: Erasca (ERAS) - The Data Lands, and So Does the Lawsuit Threat 🔒 Paid
- 2026-04-27 UPDATE: Erasca (ERAS) - The Clock is Set for Mid-May 🔒 Paid
- 2026-03-14 UPDATE: Erasca (ERAS) - Burns the Boats and Goes All-In on RAS 🔒 Paid
- 2026-03-08 UPDATE: Erasca (ERAS) - A Free Look at a Rational Combo 🔒 Paid
- 2026-02-11 Erasca (ERAS): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.